{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(14)"],"submitter":["Heinzel A"],"pubmed_abstract":["O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine (FET) is a widely used amino acid tracer for positron emission tomography (PET) imaging of brain tumours. This retrospective study and survey aimed to analyse our extensive database regarding the development of FET PET investigations, indications, and the referring physicians' rating concerning the role of FET PET in the clinical decision-making process. Between 2006 and 2019, we performed 6534 FET PET scans on 3928 different patients against a backdrop of growing demand for FET PET. In 2019, indications for the use of FET PET were as follows: suspected recurrent glioma (46%), unclear brain lesions (20%), treatment monitoring (19%), and suspected recurrent brain metastasis (13%). The referring physicians were neurosurgeons (60%), neurologists (1"],"journal":["Cancers"],"pagination":["3336"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9319157"],"repository":["biostudies-literature"],"pubmed_title":["Two Decades of Brain Tumour Imaging with O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Julich Experience."],"pmcid":["PMC9319157"],"pubmed_authors":["Rapp M","Stoffels G","Migliorini F","Weiss Lucas C","Fink GR","Piroth M","Dedic D","Maurer GD","Neumaier BN","Mottaghy FM","Tscherpel C","Dillen KNH","Worthoff WA","Clusmann H","Willuweit A","Mauler J","Galldiks N","Heinzel A","Hampl J","Delev D","Shah NJ","Rosen J","Ruge MI","Kocher M","Steinbach JP","Stegmayr C","Goldbrunner R","Herrlinger U","Eble MJ","Lohmann P","Filss CP","Lerche C","Ceccon G","Sabel M","Bauer EK","Geisler S","Dunkl V","Werner JM","Langen KJ"],"additional_accession":[]},"is_claimable":false,"name":"Two Decades of Brain Tumour Imaging with O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PET: The Forschungszentrum Julich Experience.","description":"O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine (FET) is a widely used amino acid tracer for positron emission tomography (PET) imaging of brain tumours. This retrospective study and survey aimed to analyse our extensive database regarding the development of FET PET investigations, indications, and the referring physicians' rating concerning the role of FET PET in the clinical decision-making process. Between 2006 and 2019, we performed 6534 FET PET scans on 3928 different patients against a backdrop of growing demand for FET PET. In 2019, indications for the use of FET PET were as follows: suspected recurrent glioma (46%), unclear brain lesions (20%), treatment monitoring (19%), and suspected recurrent brain metastasis (13%). The referring physicians were neurosurgeons (60%), neurologists (1","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-25T19:47:10.479Z","creation":"2022-08-06T22:39:29.38Z"},"accession":"S-EPMC9319157","cross_references":{"pubmed":["35884396"],"doi":["10.3390/cancers14143336"]}}